Fundraising Fox

BlossomHill Therapeutics

San Diego, US · Founded 2020 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

BlossomHill Therapeutics was founded in 2020 by JINGRONG JEAN CUI and Jingrong Jean Cui.

JJ
JINGRONG JEAN CUICo-founder
JJ
Jingrong Jean CuiCo-founder
YL
YISHAN LIExecutive
LP
Li Peter YishanNamed on SEC filing

Board

GL
GEORGE LEEBoard director
CG
CARL GORDONBoard director
SA
SUNDEEP AGRAWALBoard director
BC
BIHUA CHENBoard director
TS
TIMOTHY STUBBSBoard director

Investors · 1

Lilly Asia VenturesreportedHong Kongvia Hongbo Lu · board

Reported raises · per SEC filings

Form D private placements

$245.8M disclosed across 4 rounds · 2020–2025

▶$84.2MraisedDec 2025 · 47 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • GEORGE LEEDirector
  • CARL GORDONDirector
  • YISHAN LIExecutive Officer, Director
  • SUNDEEP AGRAWALDirector
  • BIHUA CHENDirector
  • TIMOTHY STUBBSDirector
  • JINGRONG JEAN CUIExecutive Officer, Director
Offering amount
$84.2M
Amount sold
$84.2M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$88.6MraisedJan 2024 · 44 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sundeep AgrawalDirector
  • Jingrong Jean CuiExecutive Officer, Director
  • Bihua ChenDirector
  • George LeeDirector
  • Carl GordonDirector
  • Yishan LiExecutive Officer, Director
  • Hongbo LuDirector
Offering amount
$100M
Amount sold
$88.6M
First sale
Dec 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$71MraisedMar 2021 · 27 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • George LeeDirector
  • Li Peter YishanExecutive Officer, Director
  • Bihua ChenDirector
  • Carl GordonDirector
  • Jingrong Jean CuiExecutive Officer, Director
Offering amount
$71M
Amount sold
$71M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJan 2021 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jingrong Jean CuiExecutive Officer, Director
  • Li Peter YishanExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Cancer Drugmaker BlossomHill Declines After $150 Million US IPO - Bloombergbloomberg.com · Aug 2026BlossomHill Therapeutics prices $150M IPO at $16 per share By Investing.comng.investing.com · Aug 2026Janus Henderson-Backed BlossomHill Raises $150 Million in IPO - Bloombergbloomberg.com · Aug 2026BlossomHill Therapeutics raises $150M in IPOaxios.com · Aug 2026BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline | Seeking Alphaseekingalpha.com · Aug 2026BlossomHill eyes $112M IPO harvest to fund Tagrisso challengerfiercebiotech.com · Aug 2026

Frequently asked questions

Who founded BlossomHill Therapeutics?
BlossomHill Therapeutics was founded by JINGRONG JEAN CUI, Jingrong Jean Cui in 2020.
Who are BlossomHill Therapeutics's investors?
BlossomHill Therapeutics's investors include Lilly Asia Ventures.
How much funding has BlossomHill Therapeutics raised?
BlossomHill Therapeutics has disclosed $245.8M raised across 4 rounds.
Where is BlossomHill Therapeutics headquartered?
BlossomHill Therapeutics is headquartered in San Diego, US.